Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E M Herman

Showing results (71-80 of 92) with videos related to

Pageof 10
Sort By:
Science (New York, N.Y.)|August 15, 1997
Corn genome initiativeM E Sorrells, O D Anderson, P S Baenziger, et al.
Haematologica|October 3, 2015
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinibAndrew H Lipsky, Mohammed Z H Farooqui, Xin Tian, et al.
Blood|April 30, 2016
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphomaNakhle S Saba, Delong Liu, Sarah E M Herman, et al.
Blood|September 5, 2015
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinibClare Sun, Xin Tian, Yuh Shan Lee, et al.
Blood|September 16, 2016
Whole exome sequencing in families with CLL detects a variant in Integrin β 2 associated with disease susceptibilityLynn R Goldin, Mary L McMaster, Melissa Rotunno, et al.
Blood|January 5, 2017
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemiaInhye E Ahn, Chingiz Underbayev, Adam Albitar, et al.
Leukemia|April 5, 2014
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II studyS E M Herman, C U Niemann, M Farooqui, et al.
Blood|June 29, 2012
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridolEmilia Mahoney, David M Lucas, Sneha V Gupta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2016
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic LeukemiaSarah E M Herman, Arnau Montraveta, Carsten U Niemann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2015
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II StudyCarsten U Niemann, Sarah E M Herman, Irina Maric, et al.
Pageof 10

Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
Science (New York, N.Y.)|August 15, 1997
Corn genome initiativeM E Sorrells, O D Anderson, P S Baenziger, et al.
Haematologica|October 3, 2015
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinibAndrew H Lipsky, Mohammed Z H Farooqui, Xin Tian, et al.
Blood|April 30, 2016
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphomaNakhle S Saba, Delong Liu, Sarah E M Herman, et al.
Blood|September 5, 2015
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinibClare Sun, Xin Tian, Yuh Shan Lee, et al.
Blood|September 16, 2016
Whole exome sequencing in families with CLL detects a variant in Integrin β 2 associated with disease susceptibilityLynn R Goldin, Mary L McMaster, Melissa Rotunno, et al.
Blood|January 5, 2017
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemiaInhye E Ahn, Chingiz Underbayev, Adam Albitar, et al.
Leukemia|April 5, 2014
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II studyS E M Herman, C U Niemann, M Farooqui, et al.
Blood|June 29, 2012
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridolEmilia Mahoney, David M Lucas, Sneha V Gupta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2016
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic LeukemiaSarah E M Herman, Arnau Montraveta, Carsten U Niemann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2015
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II StudyCarsten U Niemann, Sarah E M Herman, Irina Maric, et al.
Pageof 10